Biohaven Ltd. financial data

Symbol
BHVN on NYSE
Industry
Pharmaceutical Preparations
Location
215 Church Street, New Haven, CT
State of incorporation
Virgin Islands, British
Fiscal year end
December 31
Former names
Biohaven Research Ltd. (to 9/14/2022)
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 335 % -38.2%
Debt-to-equity 49.3 % +75.2%
Return On Equity -238 % -130%
Return On Assets -159 % -97.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 102M shares +25.1%
Common Stock, Shares, Outstanding 101M shares +24.8%
Entity Public Float 2.24B USD +127%
Common Stock, Value, Issued 1.66B USD +86.7%
Weighted Average Number of Shares Outstanding, Basic 91.2M shares +28.1%
Weighted Average Number of Shares Outstanding, Diluted 91.2M shares +28.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 796M USD +113%
General and Administrative Expense 89.2M USD +42.2%
Costs and Expenses 885M USD +103%
Operating Income (Loss) -885M USD -103%
Nonoperating Income (Expense) 17.8M USD +280%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -846M USD -106%
Income Tax Expense (Benefit) 735K USD
Net Income (Loss) Attributable to Parent -846M USD -107%
Earnings Per Share, Basic -9.28 USD/shares -62%
Earnings Per Share, Diluted -9.28 USD/shares -62%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.1M USD -60.1%
Marketable Securities, Current 387M USD +190%
Other Assets, Current 508K USD -95.8%
Assets, Current 538M USD +21.7%
Property, Plant and Equipment, Net 17.3M USD +0.75%
Operating Lease, Right-of-Use Asset 36.4M USD +16%
Intangible Assets, Net (Excluding Goodwill) 18.4M USD 0%
Goodwill 1.39M USD 0%
Other Assets, Noncurrent 39.5M USD +17%
Assets 615M USD +19.9%
Accounts Payable, Current 18M USD +15.7%
Employee-related Liabilities, Current 15.9M USD +13.6%
Accrued Liabilities, Current 51.5M USD +29.2%
Liabilities, Current 154M USD +178%
Operating Lease, Liability, Noncurrent 32.8M USD +18.9%
Other Liabilities, Noncurrent 4.66M USD +108%
Liabilities 192M USD +125%
Accumulated Other Comprehensive Income (Loss), Net of Tax 79K USD
Retained Earnings (Accumulated Deficit) -1.35B USD -170%
Stockholders' Equity Attributable to Parent 423M USD -1.06%
Liabilities and Equity 615M USD +19.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -103M USD -32.2%
Net Cash Provided by (Used in) Financing Activities 3.42M USD -87.2%
Net Cash Provided by (Used in) Investing Activities 34M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 101M shares +24.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -65.2M USD -25.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 103M USD -59.3%
Deferred Tax Assets, Valuation Allowance 304M USD +17.1%
Operating Lease, Liability 36.6M USD +18.5%
Depreciation 3.92M USD +16.4%
Payments to Acquire Property, Plant, and Equipment 440K USD -40.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -846M USD -107%
Lessee, Operating Lease, Liability, to be Paid 49.3M USD +23.9%
Operating Lease, Liability, Current 3.8M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.18M USD +29.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.14M USD +22.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +15.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.7M USD +42.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.84M USD +19.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.3M USD +4.55%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.33M USD +18.1%
Additional Paid in Capital 112M USD +182%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.45M USD -12.3%
Deferred Tax Assets, Net of Valuation Allowance 8.42M USD +11.9%